Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Dragan Kalinić, Ranko Škrbić, Duško Vulić, Svjetlana Stoisavljević-Šatara, Nataša Stojaković, Miloš P Stojiljković, Vanda Marković-Peković, Ana Golić Jelić, Nataša Pilipović-Broćeta & Nevena Divac. (2023) Eleven-Year Trends in Lipid-Modifying Medicines Utilisation and Expenditure in a Low-Income Country: A Study from the Republic of Srpska, Bosnia and Herzegovina. ClinicoEconomics and Outcomes Research 15, pages 513-523.
Read now
Read now
Saad Abdullah, Zikria Saleem & Brian Godman. (2023) Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-4.
Read now
Read now
András Inotai & Zoltán Kaló. (2019) How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 627-632.
Read now
Read now
Vanda Marković-Peković, Ranko Škrbić, Aleksandar Petrović, Vera Vlahović-Palčevski, Jana Mrak, Marion Bennie, Joseph Fadare, Hye-Young Kwon, Krijn Schiffers, Ilse Truter & Brian Godman. (2016) Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Review of Pharmacoeconomics & Outcomes Research 16:5, pages 609-618.
Read now
Read now
Kristina Garuolienė, Brian Godman, Jolanta Gulbinovič, Krijn Schiffers & Björn Wettermark. (2016) Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 149-152.
Read now
Read now
Brian Godman, Iain Bishop, Stephen M Campbell, Rickard E Malmström & Ilse Truter. (2015) Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, pages 323-330.
Read now
Read now
Alessandra Ferrario, Dragana Baltezarević, Tanja Novakovic, Mark Parker & Janko Samardzic. (2014) Evidence-based decision making in healthcare in Central Eastern Europe. Expert Review of Pharmacoeconomics & Outcomes Research 14:5, pages 611-615.
Read now
Read now
Brooke Benton, Jibril Handuleh, Katharine Harris, Mahiben Maruthappu, Preeti Patel, Brian Godman & Alexander E. Finlayson. (2014) Health in fragile states. Medicine, Conflict and Survival 30:1, pages 19-27.
Read now
Read now
Brian Godman, Iain Bishop, Alexander E Finlayson, Stephen Campbell, Hye-Young Kwon & Marion Bennie. (2013) Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 13:4, pages 469-482.
Read now
Read now
Articles from other publishers (16)
Johanna C Meyer, Sean MacBride-Stewart, Joseph O Fadare, Ammar Abdulrahman Jairoun, Mainul Haque, Amos Massele, Santosh Kumar, Israel Abebrese Sefah, Phumzile P Skosana & Brian Godman. (2022) Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. Cureus.
Crossref
Crossref
Nataša Stojaković, Ana Golić Jelić, Svjetlana Stoisavljević Šatara, Nataša Bednarčuk, Miloš P. Stojiljković & Ranko Škrbić. (2022) Characteristics and Patterns of Proton Pump Inhibitors Prescribing at the Primary Health Care. Medicina 58:11, pages 1622.
Crossref
Crossref
Dragan Kalinić, Ranko Škrbić, Duško Vulić, Nataša Stojaković, Svjetlana Stoisavljević-Šatara, Miloš P. Stojiljković, Vanda Marković-Peković, Ana Golić Jelić, Nataša Pilipović-Broćeta, Nathan D. Wong & Brian Godman. (2022) Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. Frontiers in Pharmacology 13.
Crossref
Crossref
Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin & Johanna C Meyer. (2021) Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research 10:12, pages 1019-1052.
Crossref
Crossref
Amanj Kurdi, Rachel Ann Elliott & Li-Chia Chen. (2020) Lessons from the failure of implementing the ‘Better Care Better Value’ prescribing indicator for renin–angiotensin system drugs in England: a qualitative study of general practitioners’ perceptions using behavioural change framework. BMJ Open 10:6, pages e035910.
Crossref
Crossref
Marina M Garcia, Mariana M Barbosa, Rondineli M Silva, Edna A Reis, Juliana Alvares, Francisco de Assis Acurcio, Brian Godman & Augusto A Guerra Junior. (2019) Indicator of access to medicines in relation to the multiple dimensions of access. Journal of Comparative Effectiveness Research 8:12, pages 1027-1041.
Crossref
Crossref
Vanda Marković-Peković, Ljubica Bojanić & Svjetlana Stoisavljević-Šatara. (2019) The characteristics of the outpatient utilisation of medicines in the Republic of Srpska in the period 2009-2017. Scripta Medica 50:4, pages 167-176.
Crossref
Crossref
Arianit Jakupi, Brian Godman, Antony Martin, Alan Haycox & Indrit Baholli. (2018) Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications. PharmacoEconomics - Open 2:4, pages 423-432.
Crossref
Crossref
Ljubica Bojanić, Vanda Marković-Peković, Ranko Škrbić, Nataša Stojaković, Mirjana Ðermanović, Janja Bojanić, Jurij Fürst, Amanj B. Kurdi & Brian Godman. (2018) Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Frontiers in Pharmacology 9.
Crossref
Crossref
Amanj Baker, Li-Chia Chen, Rachel A. Elliott & Brian Godman. (2015) The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research 15:1.
Crossref
Crossref
Ilse Truter, Sushma Shankar, Marion Bennie, Menno van Woerkom & Brian Godman. (2015) Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications. Journal of Comparative Effectiveness Research 4:2, pages 123-131.
Crossref
Crossref
James C. Moon, Brian Godman, Max Petzold, Samantha Alvarez-Madrazo, Kathleen Bennett, Iain Bishop, Anna Bucsics, Ulrik Hesse, Andrew Martin, Steven Simoens, Corinne Zara & Rickard E. Malmström. (2014) Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Frontiers in Pharmacology 5.
Crossref
Crossref
Steven Simoens, Kristien De Bruyn, Jamilette Miranda, Marion Bennie, Rickard E. Malmström & Brian Godman. (2013) Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research 4:3, pages 173-181.
Crossref
Crossref
B. Godman, B. Wettermark, J. Miranda, M. Bennie, A. Martin & R. E. Malmström. (2013) Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. International Journal of Clinical Practice 67:9, pages 853-862.
Crossref
Crossref
Brian Godman, Marie Persson, Jamilette Miranda, Peter Skiöld, Björn Wettermark, Corrado Barbui & Lars L. Gustafsson. (2013) Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. Applied Health Economics and Health Policy 11:4, pages 383-393.
Crossref
Crossref
Brian Godman & Lars L. Gustafsson. (2013) A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing. Applied Health Economics and Health Policy 11:1, pages 79-82.
Crossref
Crossref